(Q34628781)

3 August 2017

1 reference

title

Pharmacokinetics, efficacy and safety of aleglitazar for the treatment of type 2 diabetes with high cardiovascular risk (English)

1 reference

3 August 2017

0 references

1 reference

Lisa M Younk

1

1 reference

3 August 2017

Lisa Uhl

series ordinal

2

1 reference

3 August 2017

Stephen N Davis

series ordinal

3

1 reference

3 August 2017

language of work or name

English

0 references

publication date

27 April 2011

1 reference

Expert Opinion on Drug Metabolism & Toxicology

3 August 2017

1 reference

3 August 2017

7

1 reference

3 August 2017

6

1 reference

3 August 2017

753-763

1 reference

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group

3 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.579561

Effects of intensive glucose lowering in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.579561

Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Card

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.579561

Systematic review: glucose control and cardiovascular disease in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.579561

Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.579561

Standards of medical care in diabetes--2010.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.579561

Insulin resistance and cardiovascular events with low HDL cholesterol: the Veterans Affairs HDL Intervention Trial (VA-HIT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.579561

Diabetes, plasma insulin, and cardiovascular disease: subgroup analysis from the Department of Veterans Affairs high-density lipoprotein intervention trial (VA-HIT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.579561

Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.579561

Effects of combination lipid therapy in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.579561

Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.579561

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.579561

Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.579561

Safety considerations with fibrate therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.579561

Pharmacokinetics, pharmacodynamics, and tolerability of aleglitazar in patients with type 2 diabetes: results from a randomized, placebo-controlled clinical study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.579561

Effect of the dual peroxisome proliferator-activated receptor-alpha/gamma agonist aleglitazar on risk of cardiovascular disease in patients with type 2 diabetes (SYNCHRONY): a phase II, randomised, dose-ranging study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.579561

Fibrates and coronary risk reduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.579561

Micronised fenofibrate: an updated review of its clinical efficacy in the management of dyslipidaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.579561

Fibrates, glitazones, and peroxisome proliferator-activated receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.579561

PPARs and adipocyte function.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.579561

Peroxisome proliferator-activated receptor γ in diabetes and metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.579561

A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.579561

Regulation of human apoA-I by gemfibrozil and fenofibrate through selective peroxisome proliferator-activated receptor alpha modulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.579561

Differential activation of peroxisome proliferator-activated receptor-gamma by troglitazone and rosiglitazone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.579561

A unique PPARgamma ligand with potent insulin-sensitizing yet weak adipogenic activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.579561

The many faces of PPARgamma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.579561

Evolution of peroxisome proliferator-activated receptor agonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.579561

INT131: a selective modulator of PPAR gamma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.579561

Scaffold-based discovery of indeglitazar, a PPAR pan-active anti-diabetic agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.579561

PPAR dual agonists: are they opening Pandora's Box?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.579561

Aleglitazar, a new, potent, and balanced dual PPARalpha/gamma agonist for the treatment of type II diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.579561

Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.579561

Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.579561

Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.579561

The effect of dual PPAR alpha/gamma stimulation with combination of rosiglitazone and fenofibrate on metabolic parameters in type 2 diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.579561

Relationships between low-density lipoprotein particle size, plasma lipoproteins, and progression of coronary artery disease: the Diabetes Atherosclerosis Intervention Study (DAIS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.579561

Dual PPAR alpha/gamma agonists: promises and pitfalls in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.579561

The next generation of PPAR drugs: do we have the tools to find them?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.579561

Thiazolidinediones, insulin resistance and obesity: Finding a balance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.579561

10.1517/17425255.2011.579561

21 January 2018

Identifiers

DOI

1 reference

3 August 2017

1 reference